middle.news
PolyNovo FY26 Sales Rise 16% as NovoSorb MTX Adoption Accelerates
7:55am on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
PolyNovo FY26 Sales Rise 16% as NovoSorb MTX Adoption Accelerates
7:55am on Wednesday 26th of August, 2026 AEST
Key Points
FY26 revenue up 16.1% to AUD 150 million
Net profit after tax down 44% to AUD 7.3 million
NovoSorb MTX sales nearly double, US sales up 15.6%
New manufacturing facility completed and validated
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Polynovo (ASX:PNV)
OPEN ARTICLE